Randomized comparison of everolimus-eluting stents and sirolimus-eluting stents in patients with ST elevation myocardial infarction: RACES-MI trial.

[1]  H. Suryapranata,et al.  A meta-analytic overview of thrombectomy during primary angioplasty. , 2013, International journal of cardiology.

[2]  F. Prati,et al.  Three-year follow-up of the MULTIcentre evaluation of Single high-dose Bolus TiRofiban versus Abciximab with Sirolimus-eluting STEnt or Bare-Metal Stent in Acute Myocardial Infarction StudY (MULTISTRATEGY). , 2013, International journal of cardiology.

[3]  P. Serruys,et al.  Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial , 2012, The Lancet.

[4]  L. Räber,et al.  Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. , 2012, JAMA.

[5]  P. Smits,et al.  Objectives Background Methods Results Conclusions , 2022 .

[6]  G. Stone,et al.  Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. , 2012, Archives of internal medicine.

[7]  S. de Servi,et al.  Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials. , 2011, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[8]  B. Gersh,et al.  Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial , 2011, The Lancet.

[9]  C. Terkelsen,et al.  Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 3-year follow-up of the randomized DEDICATION (Drug Elution and Distal Protection in Acute Myocardial Infarction) Trial. , 2010, Journal of the American College of Cardiology.

[10]  D. Atsma,et al.  Three-year outcome of sirolimus-eluting versus bare-metal stents for the treatment of ST-segment elevation myocardial infarction (from the MISSION! Intervention Study). , 2010, The American journal of cardiology.

[11]  M. Nazzaro,et al.  Maintenance of long-term clinical benefit with sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction 3-year results of the SESAMI (sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction) trial. , 2010, Journal of the American College of Cardiology.

[12]  R. Ferrari,et al.  The 5-year clinical outcomes after a randomized comparison of sirolimus-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction. , 2009, Journal of the American College of Cardiology.

[13]  G. De Luca,et al.  Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial. , 2009, American heart journal.

[14]  G. De Luca,et al.  Percutaneous coronary intervention-related time delay, patient's risk profile, and survival benefits of primary angioplasty vs lytic therapy in ST-segment elevation myocardial infarction. , 2009, The American journal of emergency medicine.

[15]  G. De Luca,et al.  The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial. , 2009, JACC. Cardiovascular interventions.

[16]  G. Stone,et al.  Short and long-term benefits of sirolimus-eluting stent in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials , 2009, Journal of Thrombosis and Thrombolysis.

[17]  G. Biondi-Zoccai,et al.  Transferring patients with ST-segment elevation myocardial infarction for mechanical reperfusion: a meta-regression analysis of randomized trials. , 2008, Annals of emergency medicine.

[18]  G. Stone,et al.  Coronary stenting versus balloon angioplasty for acute myocardial infarction: a meta-regression analysis of randomized trials. , 2008, International journal of cardiology.

[19]  J. Ottervanger,et al.  Predictors and clinical implications of early reinfarction after primary angioplasty for ST-segment elevation myocardial infarction. , 2006, American heart journal.

[20]  J. Ottervanger,et al.  Is routine stenting for acute myocardial infarction superior to balloon angioplasty? A randomised comparison in a large cohort of unselected patients , 2005, Heart.

[21]  G. Parodi,et al.  Abciximab-Supported Infarct Artery Stent Implantation for Acute Myocardial Infarction and Long-Term Survival: A Prospective, Multicenter, Randomized Trial Comparing Infarct Artery Stenting Plus Abciximab With Stenting Alone , 2004, Circulation.

[22]  E. Antman,et al.  Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. , 2003, Journal of the American College of Cardiology.

[23]  J. J. Griffin,et al.  Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. , 2002, The New England journal of medicine.

[24]  J. Tijssen,et al.  5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Ele , 2011, JACC. Cardiovascular interventions.

[25]  E. Bramucci,et al.  Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty). , 2011, JACC. Cardiovascular interventions.